metabolic
Liver / metabolic
Hepatic and metabolic papers — short peptides written for liver, pancreas, and related metabolic tissue.
This chapter is metabolic tissue: liver first, then related organs the authors name as metabolic — pancreas among them — when the peptide is written for that tissue. The Khavinson library includes short peptides designed after hepatic and pancreatic extracts. Those papers file here. A general wellness essay about “metabolism” does not.
Peptide themes that belong on this hub are short chains discussed as liver- or pancreas-directed in that lineage (names you will meet include Livagen, Ovagen, and Pancragen, among others). Typical subjects are hepatocyte models, pancreatic cultures, and communications that take a named metabolic organ as the target. Whole-organism aging reviews belong under General aging.
Read the linked studies for the organ actually used, the model, and the PMID. A culture paper is not a diet. This hub will not tell you how to treat a liver or a pancreas. It will tell you which cited papers sit on this shelf.
Studies
- Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis
In two rat models of acute kidney injury (gentamicin and ischemia/reperfusion), the authors report that EDL lessened oliguria, azotemia, proteinuria, and sodium wasting and supported antioxidant enzymes.
- Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells.
In aging pancreatic and bronchial epithelial cultures, KEDW and AEDL tissue-specifically tracked promoter methylation and expression of selected transcription-factor genes — culture epigenetics, not a clinical study.
- Peptides regulate expression of signaling molecules in kidney cell cultures during in vitro aging.
In aging primary kidney cultures, a calf-kidney polypeptide complex and tripeptide AED (T-31) were reported to activate cell-renewal markers, while EDL (T-35) targeted gelatinase MMP-14.
- Prospects of using pancragen for correction of metabolic disorders in elderly people.
In 33 elderly patients with type 2 diabetes, the authors report that pancragen lowered fasting and OGTT glucose, insulin, and an insulin-resistance index; 30 healthy elderly comparators had higher nocturnal melatonin — not an RCT in the PubMed record.